Events | Screen enroll (time of randomization) | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | ICU D/C | Hospital D/C | Day 30 | Day 180 |
---|---|---|---|---|---|---|---|---|---|---|
Procedure | ||||||||||
 Eligibility Verification | X |  |  |  |  |  |  |  |  |  |
 Informed consent | X |  |  |  |  |  |  |  |  |  |
 Randomization | X |  |  |  |  |  |  |  |  |  |
 Study drug admina | X | X | X | X | X | X |  |  |  |  |
 Demographics | X |  |  |  |  |  |  |  |  |  |
 Anthropometrics | X |  |  |  |  |  |  |  |  |  |
 Source of Admission | X |  |  |  |  |  |  |  |  |  |
 History and physicalb (including comorbidity) | X |  |  |  |  |  |  |  |  |  |
 Respiratory supportb | X | X | X | X | X | X | X | X | O |  |
 Vasopressor use (each agent and dose)b,c | X | X | X | X | X | X | X | X | O |  |
 APACHE IId [71] | X |  |  |  |  |  |  |  |  |  |
 SOFA scored [72] | X | X | X | X | X | X |  |  |  |  |
 Vitalse | X | X | X | X | X | X |  |  |  |  |
 GCS [90] | X | X | X | X | X | X |  |  |  |  |
 RASS [73] | X | X | X | X | X | X |  |  |  |  |
X | X | X | X | X | X | Â | Â | Â | Â | |
 Hematology (platelets) | A | A | A | A | A | A |  |  |  |  |
 Chemistry (T. bili, creatinine) | A | A | A | A | A | A |  |  |  |  |
 Lactate | A | A | A |  |  |  |  |  |  |  |
 Coagulation | A |  |  |  |  |  |  |  |  |  |
 Pregnancy testg | X |  |  |  |  |  |  |  |  |  |
 Central research labsh | X | X | X | X | X |  |  |  |  |  |
 Antimicrobial therapyb | X |  |  |  |  |  | X | X | O |  |
 Infection source datab | X |  |  |  |  |  | X | X |  |  |
 Health-care location | X | X | X | X | X | X | X | X | O | C |
Adverse event monitoring | ||||||||||
 Potentially associated | X | X | X | X | X | X | X | X | O |  |
 Serious | X | X | X | X | X | X | X | X | O |  |
Subject completion and follow-up | ||||||||||
 Vital status |  |  |  |  |  |  | X | X | O | C |
 Renal Replacement free days |  |  |  |  |  |  |  | X | O |  |
 VVFD |  |  |  |  |  |  |  | X | O |  |
 Neuro-psychological Battery [65] |  |  |  |  |  |  |  |  |  | C |